Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II gemcitabine/cisplatin/nab-paclitaxel for biliary tract cancers with pathological lymph node metastasis
jRCTs051180178Phase 2Completed
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and paclitaxel in biliary cancer. Primary endpoints: Feasibility (Phase I): Maximum tolerated dose (MTD), Feasibility (Phase I): Recommended dose (RD) and 4 more. Started Feb 2018; status: completed.
02
Drugs
gemcitabinecisplatinpaclitaxel
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs051180178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180178.